WCM
GILD icon

Windsor Capital Management’s Gilead Sciences GILD Stock Holding History

Windsor Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-8,319
Closed -$595K – 112
2016
Q4 		$595K Buy
8,319
+171
+2% +$12.7K 0.32% 66
2016
Q3 		$644K Buy
+8,148
New +$662K 0.35% 59
2015
Q4 		– Sell
-1,461
Closed -$143K – 204
2015
Q3 		$143K Buy
+1,461
New +$162K 0.08% 110
2014
Q1 		– Sell
-1,350
Closed -$101K – 150
2013
Q4 		$101K Hold
1,350
– – 0.06% 122
2013
Q3 		$85K Hold
1,350
– – 0.05% 133
2013
Q2 		$69K Buy
+1,350
New +$70.4K 0.04% 141

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Windsor Capital Management's GILD Position: Q1 2017 in Review

Windsor Capital Management sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 8,319 shares — an estimated $595K sold.

Windsor Capital Management first reported a position in GILD in Q2 2013 and held it in 6 quarters. The position peaked at $644K in Q3 2016. 1,524 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

  • Windsor Capital Management reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
  • Windsor Capital Management sold 8,319 Gilead Sciences shares in Q1 2017, an estimated $595K.
  • Windsor Capital Management first reported a position in Gilead Sciences in Q2 2013 and held it in 6 quarters.
  • Windsor Capital Management's Gilead Sciences position peaked at $644K in Q3 2016.
  • 1,524 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on Windsor Capital Management's 13F filing for Q1 2017, filed 9 May 2017.